Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
1,839 people get CUR articles and Market Currents by email alert.
Get email alerts on CUR »
FOCUS
|
PRO
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
To learn more about Seeking Alpha Pro, click here.
-
Neuralstem: Wall Street Analyst Forum Presentation TranscriptTue, May 22, 2007 • 3 Comments
-
PR Newswire (May 28, 2013)
-
PR Newswire (May 10, 2013)
-
PR Newswire (May 8, 2013)
-
PR Newswire (Apr 29, 2013)
-
PR Newswire (Apr 24, 2013)
-
FDA Approves Neuralstem To Treat Final Cohort In NSI-189 Phase Ib Trial In Major Depressive DisorderPR Newswire (Apr 22, 2013)
-
PR Newswire (Apr 18, 2013)
-
PR Newswire (Apr 17, 2013)
-
PR Newswire (Mar 25, 2013)
-
PR Newswire (Mar 15, 2013)
-
PR Newswire (Mar 14, 2013)
-
PR Newswire (Feb 7, 2013)
-
PR Newswire (Jan 14, 2013)
-
PR Newswire (Jan 4, 2013)
CUR vs. ETF Alternatives
Company Description
Currently, there's no company description for CUR.
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Tuesday, May 28, 9:44 AM Neuralstem (CUR) says a study shows that rats transplanted with NSI-566, human neural stem cells that the company derives from the spinal chord, experienced "improvement along several measures of motor function and a reduction of spasticity." Neuralstem shares +1.4%. (PR) Comment! [Healthcare, On the Move]
- Thursday, May 16, 10:46 AM Shares of stem cell research firms are rallying today on the back of an announcement today by the Oregon Health and Science University that they've successfully reproduced human stem cells by cloning. Cloning stem cells in this fashion could lead to cell therapies using a patient’s own cells and thereby avoid the problems of immune suppression: StemCells (STEM +2.2%), NeuralStem (CUR +2.1%), NeoStem (NBS +2.2%). Comment! [Healthcare, On the Move]
- Friday, May 10, 4:31 PM Neuralstem (CUR): Q1 EPS of -$0.05 in-line. (PR) Comment! [Earnings, Breaking News, Healthcare]
- Monday, April 22, 9:46 AM Neuralstem (CUR +2.7%-) ticks higher at the open after the FDA gives the go ahead to begin dosing its third and final cohort of patients in its ongoing Phase Ib safety trials of NSI-189, a treatment for major depressive disorder. Comment! [Healthcare, On the Move]
-
Friday, April 19, 12:31 PM
Neuralstem (CUR +2.7%-) ticks higher at the open after the FDA gives the go ahead to begin dosing its third and final cohort of patients in its ongoing Phase Ib safety trials of NSI-189, a treatment for major depressive disorder.
2 Comments [Earnings, On the Move, Consumer, Global & FX] - Wednesday, April 17, 9:19 AM Neuralstem (CUR) is set to open sharply higher after saying the FDA has approved the company's request to begin a Phase II trial of NSI-566 human neural stem cells for the treatment of Lou Gehrig's disease. A Phase I study suggested the therapy interrupted the progression of the disease. Shares +11.32% Comment! [Healthcare, On the Move]
-
Wednesday, April 17, 9:12 AM
Premarket gainers: VRML +29%. ACUR +26%. OCZ +18%. CUR +9%. ALKS +9%. ABMD +9%. ASML +6%.
Losers: EOPN -29%. INWK -25%. CXW -15%. MHR -12%. ZGNX -11%. TXT -9%. CRUS -7%. VRNG -6%. 1 Comment [On the Move] - Monday, March 25, 3:43 PM Neuralstem (CUR -2.7%) slips after earlier saying it's secured $8M in debt financing from Hercules Technology to fund the company's capital budget through late 2014. The company has multiple cell therapy clinical trials planned this year, including upcoming Phase 2 ALS trials in the U.S. Comment! [Healthcare, On the Move]
- Monday, January 14, 9:41 AM Neuralstem (CUR) jumps 12.1% after it receives approval from the FDA to start a Phase I safety trial of its lead cell therapy treatment, NSI-566, in eight patients who have become complete paralyzed due to spinal-cord injuries. Neuralstem has already conducted 18 successful surgeries using the same cells and surgical device that it will use in the new trial. (PR) Comment! [On the Move, Healthcare]
-
Monday, January 14, 9:09 AM
Premarket gainers: AZK +29%. CUR +14%. AVNW +13%. HWD +11%. VRNT +10%. NICE +8%. FIO +6%. FRAN +6%. DNDN +5%. ALU +6%.
Losers: NTE -11%. CRUS -6%. Comment! [On the Move] -
Friday, December 7, 2012, 12:50 PM
Midday top 10 gainers: CBMX +184%. GTIM +48%. LTBR +18%. DLGC +17%. RECV +16%. UNXL +15%. PAMT +15%. TELK +14%. JKS +14%. XPLR +11%.
Midday top 10 Losers: TOPS -23%. AMRN -19%. KUTV -15%. VTSS -13%. MBLX -11%. CHLN -11%. CHTP -9%. RGC -8%. CUR -8%. AACC -8%. Comment! [On the Move] -
Tuesday, December 4, 2012, 12:45 PM
Midday top 10 gainers: ALDA +54%. SINO +29%. CYCC +17%. LTBR +12%. CORT +12%. SAB +11%. EDMC +10%. CPGI +11%. PRIS +10%. ACLS +10%.
Midday top 10 Losers: UEPS -56%. GERN -24%. EXA -22%. CUR -20%. SSN -19%. PPHM -16%. IQNT -18%. PBY -14%. GURE -12%. LEDS -12%. 3 Comments [On the Move] - Monday, December 3, 2012, 2:28 PM Neuralstem (CUR +7.2%) spikes, possibly related to a Crain's article reporting "amazing results" in a patient who received 500K stem cells derived by CUR. 1 Comment [On the Move, Healthcare]
- Tuesday, November 27, 2012, 12:45 PM Midday top 10 gainers: ACAD +141%. CPSL +30%. IMMR +30%. RAH +27%. TSPT +12%. BWEN +12%. CUR +12%. FOLD +10%. FONR +10%. CDTI +10%. Midday top 10 Losers: STV -11%. MMR -9%. THO -11%. RECV -10%. CBAK -9%. BLIN -12%. ENMD -8%. RGDX -8%. ARCI -8%. BV -8%. Comment!
- Wednesday, October 17, 2012, 10:35 AM Neuralstem (CUR +0.9%) starts testing the safety of its NSI-189 treatment for Major Depressive Disorder on a second set of patients after receiving FDA approval to do so. "There were no surprises" in the first cohort of patients in the Phase Ib study, the company says. (PR) Comment! [Healthcare]
-
Tuesday, October 16, 2012, 9:10 AM
Premarket gainers: NOOF +54%. THLD +12%. MUR +8%. AEGR +7%. JOEZ +7%. CUR +7%. DPZ +6%.
Losers: RATE -26%. ISIS -20%. CLWR -19%. CMRE -10%. WAC -5%. GWW -5%. 1 Comment [On the Move]
-
- View all 1 replies
-
Joseph P. Porter: So far $CUR has reported positive results, if limited in scope - but no one else is getting anywhere. Why the upset?
-
Joseph P. Porter
On a dismal day 3 companies come thru: $CUR up .07, $RNO up .31, $SLP up .09. I'll take it. - View all 0 replies
-
Joseph P. Porter
For all of its good press, would argue $CUR is undervalued - spinal cord treatments looking great. $CUR a must-buy until $3.00? - View all 0 replies
-
- View all 0 replies
-
Joseph P. Porter
$CUR had good news last week, and gained some but fell back. Will it continue on the upside this week? - View all 0 replies
-
- View all 5 replies
-
neobliviscar: Ja mata. Let me frame it then. The stock is only up +10% this week. It was up +11%, except for that Charlie Sheen Violent Torpedo of Truth. -
-
ggoldsmith
$CUR: Any thoughts about the value of the new NFL sponsorship of CUR's stock. Will this bring any money to them? - View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
Joseph P. Porter
$ONTY up $0.20+. Must be some kind of record. $CUR up, should be reporting on some of its research soon. - View all 0 replies
LATEST REPLIES
-
- View all 1 replies
-
Joseph P. Porter: So far $CUR has reported positive results, if limited in scope - but no one else is getting anywhere. Why the upset?
-
- View all 5 replies
-
neobliviscar: Ja mata. Let me frame it then. The stock is only up +10% this week. It was up +11%, except for that Charlie Sheen Violent Torpedo of Truth.
-
-
- View all 1 replies
-
Robbster: Tthese represent my "Dev. Biotech Fundamentals" strategy; breakthrough science, financials and leadership that support price appreciation.
-
- View all 5 replies
-
-
-
Joseph P. Porter
So much for that. AGNC down $.29, all REITs down. My bioPharms both up (PFE & CUR). Too bad BioPharms don't pay big divs. - View all 2 replies
-
wallstreetpro2: yep all my reit went down to NYMT ARR MTGE AGNC usually in bad tape they been going up -
-
Joseph P. Porter
CUR drops price to $1 on secondary release. A bit more than expected. Is it a big mistake? ($1.25 would have been better.) - View all 1 replies
-
-
- View all 2 replies
-
-
johnjail: nice pipeline and nice last quarter :) but I didn't find the cash they have and the burn rate. at that price seems to be interesting